URMD -- Huge market potential Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : URMD -- Huge market potential

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: george who wrote (121)	11/6/1997 12:12:00 PM
From: Ken M	Read Replies (1) of 369

Uromed (NASDAQ:URMD) CaverMap Aid gets FDA approval Reuters, Thursday, November 06, 1997 at 11:41 NEEDHAM, Mass., Nov 6 (Reuters) - UroMed Corp said Thursday the U.S. Food and Drug Administration cleared its nerve locating product, the CaverMap Surgical Aid, for U.S. marketing and distribution. The company said patients are usually treated for prostate cancer with radical surgery and that the most frequent complication is impotence, often caused by nerve damage. The CaverMap is intended to guide surgeons in mapping and ultimately sparing cavernous nerves which are responsible for potency. Uromed estimates that about 334,500 new prostate cancer cases will be diagnosed in the U.S. and that over 60 percent of these cases will have localized cancer that may benefit from surgery or radiation treatment. The company said it plans to introduce the CaverMap to clinics early next year. Copyright 1997, Reuters News Service Companies or Securities discussed in this article: SymbolNameNASDAQ:URMDUromed Corp

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next